Related Experiment Video
Updated: Dec 10, 2025

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Growth hormone treatment for Prader-Willi syndrome: A review
1Gritscience Biopharmaceuticals Co., Ltd, Life Science Park Road, Changping District, Beijing, China.
Insights
Growth hormone (GH) treatment improves physical aspects of Prader-Willi Syndrome (PWS) but shows limited effects on cognitive and behavioral issues. Further research is needed to explore GH
Area of Science:
- Genetics and Developmental Disorders
- Pediatric Endocrinology
Background:
- Prader-Willi Syndrome (PWS) is a rare genetic disorder causing hypotonia, developmental delay, cognitive impairment, and hyperphagia leading to obesity.
- Growth hormone (GH) deficiency is common in PWS, and GH treatment is standard for improving physical development.
- Existing research confirms GH benefits for motor development, body composition, and linear growth in PWS.
Purpose of the Study:
- To systematically review recent clinical trials on GH treatment in Prader-Willi Syndrome patients.
- To emphasize the impact of GH treatment on mental flexibility and behavioral problems in PWS.
- To discuss concerns regarding the initiation of GH therapy and suggest future research directions.
Main Methods:
- Systematic analysis of recent clinical trials involving GH treatment for PWS.
- Focus on studies reporting mental and behavioral outcomes alongside physical changes.
- Literature review to identify current trends and gaps in PWS research.
Main Results:
- GH treatment significantly improves motor development, body composition, and linear growth in PWS.
- Evidence for significant improvements in mental flexibility and behavioral problems remains limited.
- Concerns regarding the initiation and long-term effects of GH treatment require careful consideration.
Conclusions:
- GH treatment is beneficial for the physical phenotype of PWS but has minimal impact on cognitive and behavioral aspects.
- Further basic and clinical research is essential to understand and address the neurological and behavioral challenges in PWS.
- Future studies should explore novel therapeutic targets and refine GH treatment protocols for PWS.
Abstract:
The Prader-Willi Syndrome (PWS) is a rare developmental disorder that contributed by multiple genes. Phenotypically, infants with PWS exhibit hypotonia and developmental delay, whilst older children and adults have cognitive impairments, neuropsychiatric symptoms, impaired motor development, neurological anomalies, endocrine dysfunctions like growth hormone (GH) deficiency, and hyperphagia that leads to obesity. Although mechanisms remain elusive, GH treatment has been recommended as the standard treatment for PWS children. In addition to better motor development, improved body composition and linear growth have been well established, but mental flexibility and behavioural problems remained largely untouched. This review will systemically analyze the recent clinical trials of GH treatment on PWS patients. The emphasis is on the mental and behavioural improvements by GH treatment, and a few concerns to initiate GH treatment. This review will finally propose possible future explorations on basic studies that may shed new light on clinical trials of GH treatment on PWS.
Related Concept Videos
Hypoglycemia and Glucagon
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Gene Therapy
What is Genetic Engineering?
Nature and Nurture

